surpass 2 tirzepatide Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist in patients with type diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial TIRZEPATIDE (COAGONISTA GIP/GP1): DESARROLLO CLINICO
Pay in 4 interest-free payments of $5.56 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23




























